<head>
    <meta charset="utf-8">
    <meta name="width=device-width,initial-scale=1">
    <title>Vira land Host factors</title>
</head>
<body background="https://aecm.eu/wp-content/uploads/2019/06/covid-3.jpg">
    <ul>
        <li><a href="Covid-19.html">Home Page</a></li>
        <li><a href="signs &Sympotomps.html">Signs_and_symptoms</a></li>
        <li><a href="Causes.html">Causes</a></li>
        <li><a href="viral.html">Viral</a></li>
        
                </ul>
    <span class="mw-headline" id="Viral_and_host_factors">Viral and host factors</span>
    <h4><span class="mw-headline" id="Virus_proteins">Virus proteins</span></h4>
    <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/1/17/Fpubh-08-00383-g004.jpg/800px-Fpubh-08-00383-g004.jpg">
    <p>Multiple viral and host factors affect the pathogenesis of the virus. The S-protein, otherwise known as the spike protein, is the viral component that attaches to the host receptor via the <a href="/wiki/Angiotensin-converting_enzyme_2" title="Angiotensin-converting enzyme 2">ACE2</a> receptors. It includes two subunits: S1 and S2. S1 determines the virus-host range and cellular tropism via the receptor-binding domain. S2 mediates the membrane fusion of the virus to its potential cell host via the H1 and HR2, which are <a href="/wiki/Heptad_repeat" title="Heptad repeat">heptad repeat</a> regions. Studies have shown that S1 domain induced <a href="/wiki/IgG" class="mw-redirect" title="IgG">IgG</a> and <a href="/wiki/IgA" class="mw-redirect" title="IgA">IgA</a> antibody levels at a much higher capacity. It is the focus spike proteins expression that are involved in many effective COVID-19 vaccines.<sup id="cite_ref-pmid33340022_96-0" class="reference"><a href="#cite_note-pmid33340022-96">[96]</a></sup>
    </p>
    <p>The M protein is the viral protein responsible for the transmembrane transport of nutrients. It is the cause of the bud release and the formation of the viral envelope.<sup id="cite_ref-:6_97-0" class="reference"><a href="#cite_note-:6-97">[97]</a></sup> The N and E protein are accessory proteins that interfere with the host's immune response.<sup id="cite_ref-:6_97-1" class="reference"><a href="#cite_note-:6-97">[97]</a></sup>
    </p>
    <h4><span class="mw-headline" id="Host_factors">Host factors</span></h4>
    <p>Human <a href="/wiki/Angiotensin_converting_enzyme_2" class="mw-redirect" title="Venous thromboembolism">angiotensin converting enzyme 2</a> (hACE2) is the host factor that SARS-COV2 virus targets causing COVID-19. Theoretically the usage of <a href="/wiki/Angiotensin_II_receptor_blocker" title="Angiotensin II receptor blocker">angiotensin receptor blockers</a> (ARB) and <a href="/wiki/ACE_inhibitor" title="">ACE inhibitors</a> upregulating ACE2 expression might increase morbidity with COVID-19, though animal data suggest some potential protective effect of ARB. However no clinical studies have proven susceptibility or outcomes. Until further data is available, guidelines and recommendations for hypertensive patients remain.<sup id="cite_ref-98" class="reference"><a href="#cite_note-98">[98]</a></sup>
    </p>
    <p>The effect of the virus on ACE2 cell surfaces leads to leukocytic infiltration, increased blood vessel permeability, alveolar wall permeability, as well as decreased secretion of lung surfactants. These effects cause the majority of the respiratory symptoms. However, the aggravation of local inflammation causes a cytokine storm eventually leading to a <a href="/wiki/Systemic_inflammatory_response_syndrome" title="Systemic inflammatory response syndrome">systemic inflammatory response syndrome</a>.<sup id="cite_ref-99" class="reference"><a href="#cite_note-99">[99]</a></sup>
    </p>
    <p>Among healthy adults not exposed to SARS-CoV-2, about 35% have CD4+ <a href="/wiki/T_cell" title="T cell">T cells</a> that recognize the SARS-CoV-2 <a href="/wiki/Peplomer" title="Peplomer">S protein</a> (particularly the S2 subunit) and about 50% react to other proteins of the virus, suggesting <a href="/wiki/Cross-reactivity" title="Cross-reactivity">cross-reactivity</a> from previous <a href="/wiki/Common_cold" title="Common cold">common colds</a> caused by other coronaviruses.<sup id="cite_ref-100" class="reference"><a href="#cite_note-100">[100]</a></sup>
    </p>
    <h3><span class="mw-headline" id="Viral_testing">Viral testing</span></h3>
<img src="https://upload.wikimedia.org/wikipedia/commons/thumb/7/7b/Infektionsschutzzentrum_im_Rautenstrauch-Joest-Museum%2C_K%C3%B6ln-6313_%28cropped%29.jpg/800px-Infektionsschutzzentrum_im_Rautenstrauch-Joest-Museum%2C_K%C3%B6ln-6313_%28cropped%29.jpg">
<p>The standard methods of testing for presence of SARS-CoV-2 are <a href="/wiki/Nucleic_acid_test" title="Nucleic acid test">nucleic acid tests</a>,<sup id="cite_ref-pmid32621814_105-2" class="reference"><a href="#cite_note-pmid32621814-105">[105]</a></sup><sup id="cite_ref-20200130cdc_108-0" class="reference"><a href="#cite_note-20200130cdc-108">[108]</a></sup> which detects the presence of viral RNA fragments.<sup id="cite_ref-WHO_InterimGuidance_109-0" class="reference"><a href="#cite_note-WHO_InterimGuidance-109">[109]</a></sup> As these tests detect RNA but not infectious virus, its "ability to determine duration of infectivity of patients is limited."<sup id="cite_ref-2k0iS_110-0" class="reference"><a href="#cite_note-2k0iS-110">[110]</a></sup> The test is typically done on respiratory samples obtained by a <a href="/wiki/Nasopharyngeal_swab" title="Nasopharyngeal swab">nasopharyngeal swab</a>; however, a nasal swab or sputum sample may also be used.<sup id="cite_ref-CDC2020Testing_111-0" class="reference"><a href="#cite_note-CDC2020Testing-111">[111]</a></sup><sup id="cite_ref-20200129cdc_112-0" class="reference"><a href="#cite_note-20200129cdc-112">[112]</a></sup> Results are generally available within hours.<sup id="cite_ref-pmid32621814_105-3" class="reference"><a href="#cite_note-pmid32621814-105">[105]</a></sup> The WHO has published several testing protocols for the disease.<sup id="cite_ref-113" class="reference"><a href="#cite_note-113">[113]</a></sup>
</p>
<p>Several laboratories and companies have developed serological tests, which detect antibodies produced by the body in response to infection. Several have been evaluated by <a href="/wiki/Public_Health_England" title="">Public Health England</a> and approved for use in the UK.<sup id="cite_ref-independent9515466_114-0" class="reference"><a href="#cite_note-independent9515466-114">[114]</a></sup>
</p>
<p>The <a href="/wiki/University_of_Oxford" title="University of Oxford">University of Oxford</a>'s CEBM has pointed to mounting evidence<sup id="cite_ref-yFMEP_115-0" class="reference"><a href="#cite_note-yFMEP-115">[115]</a></sup><sup id="cite_ref-2exX5_116-0" class="reference"><a href="#cite_note-2exX5-116">[116]</a></sup> that "a good proportion of 'new' mild cases and people re-testing positives after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with" and have called for "an international effort to standardize and periodically calibrate testing"<sup id="cite_ref-PQGAv_117-0" class="reference"><a href="#cite_note-PQGAv-117">[117]</a></sup> On 7<span class="nowrap">&nbsp;</span>September, the UK government issued "guidance for procedures to be implemented in laboratories to provide assurance of positive SARS-CoV-2 RNA results during periods of low prevalence, when there is a reduction in the predictive value of positive test results".<sup id="cite_ref-9Kblp_118-0" class="reference"><a href="#cite_note-9Kblp-118">[118]</a></sup>
</p>
</body>
</html>